NDA 021321 · Vantive US Hlthcare
Extraneal
Icodextrin · Intraperitoneal
NovelOrphanLast checked: Nov 20, 2026Latest source record: Apr 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Dec 20, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
31
4 Phase 3, 2 recruiting
FAERS reports
31,086
25,996 serious, 10,082 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2025.
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET) [see Clinical Pharmacology ( 12 ), Clinical Studies ( 14 )]. • For a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. ( 1 ) • To improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET). ( 1 )
Mechanism: EXTRANEAL is an isosmotic peritoneal dialysis solution containing glucose polymers (icodextrin) as the primary osmotic agent. Icodextrin functions as a colloid osmotic agent to achieve ultrafiltration during long peritoneal dialysis dwells. Icodextrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration throughout the dwell. Like other peritoneal dialysis solutions, EXTRANEAL also contains electrolytes to help normalize electrolyte balance and lactate to help normalize acid-base status.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2004 Supplement 10 · Efficacy · priority review LabelLetter
- Dec 20, 2002 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLabelLetter
1 products under this application
- EXTRANEAL · ICODEXTRIN 7.5GM/100ML · SOLUTION, INTRAPERITONEAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Icodextrin" as an intervention, any sponsor and status, largest first.
- Does Icodextrin Reduce the Risk of Small Bowel Obstruction?Pivotal-lookingStatus unknown
Uppsala UniversityAcademic, hospital or other
NCT02318888 · 1,808 participants · Start Dec 2009 · Primary completion Dec 2022
Drug: Icodextrin · For: Surgical Adhesions
Sites: Eskilstuna, Sweden; Falun, Sweden; Gävle, Sweden · 13 sites in all
- Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal DialysisPivotal-lookingRecruiting
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05721404 · 194 participants (planned) · Start May 24, 2023 · Primary completion Apr 28, 2027
Drug: Icodextrin Peritoneal Dialysis Solution; Hypertonic Dextrose solution · For: Peritoneal Dialysis
Sites: Guangzhou, China
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.Pivotal-lookingRecruiting
Iperboreal Pharma SrlIndustry
NCT03994471 · 170 participants (planned) · Start Dec 14, 2022 · Primary completion Dec 31, 2026
Drug: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght; 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution · For: End Stage Renal Disease
Sites: Aalborg, Denmark; Aarhus, Denmark; Roskilde, Denmark · 41 sites in all
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD PatientsPivotal-lookingCompleted
Vantive Health LLCIndustry
NCT00567489 · 137 participants · Start Jan 2008 · Primary completion Jul 2011
Drug: Physioneal; Dianeal and 2 more · For: ESRD; Diabetes; CAPD and 1 more
Sites: Shatin, Hong Kong; Tai Po, Hong Kong; Kowloon, Hong Kong · 19 sites in all
- Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.Pivotal-lookingCompleted
Pr Eric GoffinAcademic, hospital or other
NCT01944852 · 117 participants · Start Mar 2013 · Primary completion Feb 28, 2020
Drug: Icodextrin · For: Renal Insufficiency
Sites: Brussels, Belgium
- Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal DialysisPivotal-lookingCompleted
Yonsei UniversityAcademic, hospital or other
NCT01170858 · 100 participants · Start Aug 2010 · Primary completion Aug 2014
Drug: Icodextrin PD solution; glucose solutions · For: End Stage Renal Disease
Sites: Seoul, South Korea
Fundación Renal Iñigo Alvarez De ToledoAcademic, hospital or other
NCT00369096 · 76 participants (planned) · Start Sep 2006 · Primary completion Nov 2008
Drug: bemiparin 3500 IU/day · For: Peritoneal Diseases
Sites: Málaga, Spain; Barcelona, Spain; Sabadell, Spain · 17 sites in all
St. Joseph's Healthcare HamiltonAcademic, hospital or other
NCT01045980 · 74 participants · Start Aug 1, 2010 · Primary completion May 15, 2016
Drug: Bioimpedance and Vitamin D; Usual care and placebo and 1 more · For: Disorders Associated With Peritoneal Dialysis
Sites: Hamilton, Canada · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death6,024
- peritonitis1,914
- peritoneal dialysis complication1,499
- peritonitis bacterial1,496
- hypotension1,194
- pneumonia975
- myocardial infarction971
- infection809
- sepsis747
- fluid overload728
- fall715
- abdominal pain680
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 76 |
| 2006 | 78 |
| 2007 | 158 |
| 2008 | 364 |
| 2009 | 670 |
| 2010 | 1,121 |
| 2011 | 1,506 |
| 2012 | 1,649 |
| 2013 | 3,026 |
| 2014 | 4,314 |
| 2015 | 4,658 |
| 2016 | 3,141 |
| 2017 | 2,331 |
| 2018 | 1,252 |
| 2019 | 1,230 |
| 2020 | 1,192 |
| 2021 | 738 |
| 2022 | 711 |
| 2023 | 712 |
| 2024 | 773 |
| 2025 | 738 |
| 2026 | 587 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- End stage renal disease.
Hall YN, Chertow GM · BMJ Clin Evid 2007 · Systematic Review
- Biocompatible dialysis fluids for peritoneal dialysis.
Htay H, Johnson DW, Wiggins KJ, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Systematic Review
- Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y, Johnson DW, Craig JC, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Systematic Review
- Fluid and pharmacological agents for adhesion prevention after gynaecological surgery.
Metwally M, Watson A, Lilford R, et al. · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Use of new peritoneal dialysis solutions in children.
Canepa A, Verrina E, Perfumo F · Kidney Int Suppl 2008 · Clinical Trial, Comparative Study
- Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution.
Kerr DJ, Young AM, Neoptolemos JP, et al. · Br J Cancer 1996 · Clinical Trial, Clinical Trial, Phase I
Sponsor: Vantive US Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.